An adult woman with pseudopseudohypoparathyroidism had a child with normal calcium and parathyroid hormone concentrations and cyclic AMP response to injected parathyroid hormone in infancy. By 
The classical phenotype in pseudohypoparathyroidism (PHP) and pseudopseudohypoparathyroidism (PPHP) includes short stature, rounded facies, obesity, subcutaneous and basal ganglia calcification, mental retardation, cataracts, and a characteristic brachydactyly that particularly affects the metacarpals, metatarsals, and distal phalanges of the first digits. These Her second child was born at term, and had an uncomplicated neonatal period. She has shown normal psychomotor development, and at 6 years of age is phenotypically normal, growing along the 25th centile for height with no skeletal abnormalities, and has normal blood biochemistry.
Her third child was born after premature labour at 34 weeks' gestation with delivery by caesarean section for breech presentation and fetal distress and weighed 2600 g. He developed respiratory distress syndrome, was ventilated for the first 10 days of life, and subsequently developed bronchopulmonary dysplasia with continuing oxygen dependency to 4 weeks of age. In the first week he also had transient hypoglycaemia and jaundice requiring phototherapy. Routine TSH screening was normal. Trends in calcium and phosphate over the first three years of life are shown in fig 2. In infancy (age 3 months) he had normal calcium and parathyroid hormone 
The onset of hypocalcaemia in PHP is highly variable, from the neonatal period onwards.
Our child showed an early tendency to hyperphosphataemia but at that time calcium and parathyroid hormone concentrations were normal, and the cyclic AMP response to injected parathyroid hormone was similar to other young infants.3 By 2-6 years there was unequivocal evidence of parathyroid hormone resistance, with an absent cyclic AMP response to the injected parathyroid hormone. Such a documented change in cyclic AMP response from normal to abnormal has not been previously described. It is ofnote that he also developed hypothyroidism at a similar age with a presumed defect in TSH binding and response.
Increasing parathyroid hormone concentrations may be a protective compensation for impending hypocalcaemia due to a progressive parathyroid hormone receptor defect. Most patients with PHP type 1 have a demonstrable deficiency of the guanine nucleotide binding protein (G protein) which stimulates adenyl cyclase, while others are thought to have a postreceptor defect. Unfortunately serial G protein concentrations are not available in our child, as it would be extremely interesting to correlate any changes in G protein with changes in parathyroid hormone responsiveness.
There is a recognised association with other endocrinopathies including hypothyroidism, gonadotrophin secretory abnormalities,4 and growth hormone releasing factor deficiency. The picture is thus one of a heterogeneous set of defects in hormone related cyclic AMP generation. The ontogeny of these systems and the defects that arise therein await further clarification. Molecular genetic studies of the genes encoding for PHP type 1 and the parathyroid hormone receptor are providing information about the basis for the phenotypic variations in this group of conditions.5 6 The two affected members in the family reported here differed in their parathyroid hormone responsiveness. In this child evidence of a transition to parathyroid hormone resistance in terms of the cyclic AMP response to parathyroid hormone has been demonstrated for the first time.
Patients with PPHP are unpredictable in their susceptibility to develop hypocalcaemia and should be kept under long term review.
